What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · PFE, XBI

Pfizer bets $10.5 billion on Innovent's cancer drugs — ride the pharma deal wave

Innovent Biologics jumped 10% after signing a deal with Pfizer worth up to $10.5 billion to develop cancer drugs together.

Idea

A $10.5 billion deal with Pfizer is enormous for a Chinese biotech company — it signals that big pharma sees major value in Innovent's drug pipeline. Deals of this size often trigger analyst upgrades and attract institutional investors who previously overlooked the stock. Pfizer's involvement also de-risks the story because they're sharing the cost and expertise of drug development. The broader biotech sector tends to get a halo effect when a mega-deal like this lands, so ETFs like XBI could catch a bid too.

Key details

PFE XBID#biotech#pharma_deals#momentum

Community

Upvotes

Views

Copies

Cosigns

News sources

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion — CNBC

Related ideas

Massive $5.4 billion floods into chip stocks — ride the wave on SOXX
Tesla finally delivers on its decade-old promise — ride the AI momentum into Nvidia instead
Trillion-dollar chip giant SK Hynix hits Wall Street — ride the IPO momentum

PFE trade ideas
XBI trade ideas
Latest market news